Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

AREV Life Sciences Global Corp. (AREVF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1555-0.0055 (-3.42%)
At close: 03:01PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1610
Open0.1555
BidN/A x N/A
AskN/A x N/A
Day's Range0.1555 - 0.1555
52 Week Range0.0655 - 0.3262
Volume9,500
Avg. Volume1,775
Market Cap6.556M
Beta (5Y Monthly)2.04
PE Ratio (TTM)N/A
EPS (TTM)-0.0690
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Kevin Phelps, CPA Appointed Chief Operating Officer of Arev Life Sciences Global Corporation & Warrant Offering

    VANCOUVER, BC , April 21, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) (“AREV” or the “Company”) AREV Life Sciences Global Corporation announced today the appointment of Kevin Phelps, CPA as Chief Operating Officer. In its current phase of growth and development, AREV Life Sciences Global Corporation appoints Kevin Phelps, CPA and AREV Board Member to the role of Chief Operating Officer. Kevin Phelps brings 40 years of experience in biotec

  • GlobeNewswire

    AREV Life Sciences Global Corporation announces engagement of TransBIOTech to facilitate preclinical therapeutic pipeline development

    VANCOUVER, British Columbia, April 21, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) (“AREV” or the “Company”) announced today its initial research engagement with TransBIOTech. Created in 1999, TransBIOTech is a publicly supported preclinical research organization that works in partnership with and is supported by the Canadian government through the Natural Sciences and Engineering Research Council (NSERC) in collaboration with the Canadia

  • GlobeNewswire

    AREV Life Sciences Completes Lab and Fungi Fruiting Room Build

    VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- via InvestorWire - AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) (“AREV” or the “Company”) announces today completion of its fungi inoculation lab, colonizing and fruiting rooms. The fruiting room has been populated with colonized blocks of Lion's Mane (Hericium erinaceus) containing bioactive substances with beneficial effects on the body, especially the brain, heart and gut. Over the past 3 months, AREV has been building

Advertisement
Advertisement